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Abstract
Background/Aims: Ruthenium plaques are used for the 
treatment of ocular tumors. The aim of this work is the com-
parison between simulated absorbed dose distributions tal-
lied in an anthropomorphic phantom, obtained from ideal 
homogeneous plaques, and real eye plaques in which the 
actual heterogeneous distribution of 106Ru was measured. 
The placement of the plaques with respect to the tumor lo-
cation was taken into consideration to optimize the effec-
tiveness of the treatment. Methods: The generic CCA and 
CCB, and the specific CCA1364 and CCB1256 106Ru eye 
plaques were modeled with the Monte Carlo code PENELO-
PE. To compare the suitability of each treatment for an an-
terior, equatorial and posterior tumor location, cumulative 
dose-volume histograms for the tumors and structures at 
risk were calculated. Results: Eccentric placements of the 
plaques, taking into account the inhomogeneities of the 
emitter map, can substantially reduce the dose delivered to 
structures at risk while maintaining the prescribed dose at 
the tumor apex. Conclusions: The emitter map distribution 
of the plaque and the computerized tomography of the pa-
tient used in a Monte Carlo simulation allow an accurate de-
termination of the plaque position with respect to the tu-
mor with the potential to reduce the dose to sensitive struc-
tures. © 2018 S. Karger AG, Basel
Introduction
Brachytherapy with 106Ru eye applicators is a standard 
technique used for the treatment of uveal melanomas, the 
most common primary intraocular tumor. Although the 
use of 106Ru applicators on uveal melanomas has been 
clinically studied, there is still a lack of precise knowledge 
on how the absorbed dose distribution in the tumor vol-
ume and the surrounding structures at risk determines 
the clinical outcome [1–5]. Obviously, misplacement of 
the plaque can cause underdosing of the tumor and the 
inclusion of structures at risk into the high-dose volume, 
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resulting in less than optimal tumor control probability 
and enhanced side effects. 
The Monte Carlo method is considered the gold stan-
dard for computing absorbed dose distributions, espe-
cially for small radiation fields [6, 7], the type of fields 
involved in eye treatments. During the last two decades, 
Monte Carlo algorithms have been used in some investi-
gations to simulate the radiation transport process pro-
duced from 106Ru eye plaques and to determine the result-
ing dose distributions [8–19]. It is assumed that the emit-
ter substance in the plaque is homogeneously distributed. 
Also, most of them approximate the anatomy of the eye 
to a homogeneous water sphere where the anatomical 
structure of the eye and its corresponding structures at 
risk are not accounted for. Although some of the most 
recent works [15, 16] take into consideration the struc-
tures at risk, they still assume that the radioactive emitter 
substance is homogeneously distributed. Finally, Zarago-
za et al. [20] determined the dose over a water phantom 
using a fine-grain probability map emission of the emitter 
substance previously measured over a specific CCA 
(CCA1364) and a CCB (CCB1256) eye plaque.
It is also well known that different applicator types re-
sult in different dose distributions. However, the influ-
ence of the individual distribution of the activity at the 
surface of individual applicators of the same size has not 
been fully investigated up to now. In fact, each individual 
eye plaque presents a different distribution of the emitter 
substance, hence, leading to slightly different 3D ab-
sorbed dose distributions from one applicator to another. 
In this study, we investigate the potential clinical benefit 
of considering such differences. Thus, in order to accu-
rately plan a specific treatment, the emitter distribution 
of the individual eye plaque is required.
Methods and Materials
Geometry of the Plaques
The eye plaques considered in this work are the CCA1364 and 
the CCB1256 from the manufacturer BEBIG (Eckert & Ziegler BE-
BIG, Berlin, Germany). Both models are shaped as spherical caps 
obtained from a sphere of radius of 12.0 mm. The geometric dif-
ference between the plaques is the outer diameter of the shell 
across the rim, i.e., 15.5 mm for the CCA model and 20.2 mm for 
the CCB model. The plaques’ structure, which is 1.0 mm thick in 
total, is divided into 3 layers. The thickness of each layer, from the 
inner to the outer surface, is 0.1, 0.2, and 0.7 mm. The layers are 
made of silver, with the middle layer containing the radioactive 
material, which is electrolytically deposited over its inner surface. 
The middle (active) layer is encapsulated between the inner (win-
dow) and the outer (shielding) layers and does not cover the whole 
cap, but it reaches up to 0.7 mm from the shell rim. For both 
plaques, the distribution of the emitter substance has been mea-
sured at the Technical University of Dortmund with a device spe-
cifically developed for this purpose [21]. The geometrical descrip-
tions of the plaques [22] were accurately modeled using the con-
structive quadric geometry package provided with the gen- 
eral-purpose Monte Carlo radiation transport simulation code PE-
NELOPE [23]. For comparison purposes, the idealized CCA and 
CCB plaques with a homogeneous emitter map were also simu-
lated. The accuracy of our simulation system for eye plaques was 
previously validated by comparison of the simulated data in a wa-
ter phantom with experimental results [10, 15]. The activities of 
the plaques used were those measured by the manufacturer and 
reported in the respective certificates, namely 11.6 MBq for the 
CCA1364 and 27.3 MBq for the CCB1256.
Simulation Codes
The radioactive isotope of 106Ru disintegrates into 106Rh pro-
ducing a beta spectrum characterized by a maximum energy of 39 
keV and a half-life of 368 days [24]. Then 106Rh decays into stable 
106Pd producing a beta spectrum used for therapy. It is character-
ized by a maximum energy of 3.540 MeV and a half-life of 29.8 s.
Simulations were run with the PENELOPE (2008) code [23, 25] 
using penEasy (2010–09-07) [26] as the main steering program. 
penEasy was modified in two ways in order to simulate a beta decay 
spectrum and a heterogenous radiation source. To simulate the 
beta decay, an adapted version of the EFFY code [27], which uses 
the Fermi theory to describe the beta decay, was incorporated into 
the penEasy code. This modification allows to simulate the decay 
of 106Rh into 106Pd through the five disintegrations with the highest 
yields, i.e., 3.540 MeV (78.6%), 3.050 MeV (8.1%), 2.410 MeV 
(10.0%), 2.000 MeV (1.77%), and 1.539 MeV (0.46%). The second 
modification allows penEasy to randomly sample a position and a 
flight direction for each primary particle sampled over the plaque 
surface according to the probability distributions derived from the 
experimental heterogeneous emitter maps.
Voxelized Geometry
The fact that an emmetropic eyeball does not vary from one 
individual to another [28] allows to select a computerized tomog-
raphy scan of an anonymized adult patient as an anthropomorphic 
voxelized phantom. This phantom has been used in previous 
works [16, 29, 30]. The computerized tomography scan has 256 × 
256 × 59 voxels of 0.03125 × 0.03125 × 0.1 cm3 size. Using the 
calibration curve of the computerized tomography scanner, Houns- 
field numbers were converted into mass density values and three 
materials were chosen: air, water, and bone. penEasy allows to 
overlap quadric surfaces, those ones used to model the plaque as a 
spherical cap, on a voxelized geometry that one employed to rep-
resent the patient. This feature is used to simulate the geometry of 
the eye plaque positioned inside the voxelized human phantom.
Tumors and Sclera Segmentation
The general criteria used to select an appropriate plaque type 
for treatment is the basal diameter of the tumor, which determines 
the plaque size. The apical height of the tumor determines the ir-
radiation time and the suitability of 106Ru. In this work, the crite-
rion selected to model the tumors was to maintain the basal diam-
eter of 10.0 mm constant and to vary the apical height due to the 
fact that the tumor height is the critical parameter in a treatment. 
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These tumor volumes were modeled using a general paraboloid 
truncated by a sphere which coincided with the inner sclera sur-
face. For segmentation purposes, we consider as sclera the spher-
ical cap volume limited by the surfaces that contain, in the inner 
side, the base of the tumor and, in the outer side, the inner surface 
of the plaque. This spherical cap contains the anatomical sclera, 
some episcleral soft tissue and a safety margin that varies from 0.5 
to 1 mm, depending on the variations of the thickness of the ana-
tomical sclera in the different regions around the ocular globe. 
The whole volume considered was modeled with a thickness of 1.7 
mm.
Although quadric surfaces were used as boundary surfaces to 
define all the significant elements in the segmentation process (i.e., 
tumors, sclera, and structures at risk), all these structures are de-
fined in the computerized tomography and, as a consequence, 
many voxels are crossed by the quadrics. To consider if a given 
voxel is part or not of a segmented structure, the position of the 
center of the voxel is used as the belonging criterion. As a result of 
the above, both the thickness of the sclera and the tumor volume 
are determined by the voxelized segmentation. Therefore, the 
scleral thickness is not constant as it varies from approximately 1.2 
to 2.1 mm, depending on the number of voxels included between 
the two spherical surfaces that define it. This variation is in agree-
ment with the default value of 1.5 mm used in the code EYEPLAN 
[31, 32]. For the same reason, the apical height of a tumor can vary 
up to 0.5 mm from the quoted value. Since the eye plaques are de-
fined as spherical caps with quadric surfaces, they are not affected 
by the approximations inherent to voxelized geometries, thus their 
thickness is constant.
Tumor Positioning and Plaque Placement
Tumor positioning was selected according to the maximum 
eye diameter in the axial plane of the computerized tomography. 
This means that the tumor symmetry axis and the eye diameter 
are coplanar. The equatorial plane of the eye was determined 15° 
above the horizontal axis of the computerized tomography and 
this plane contains the center of the eye. Tumors were placed in 3 
positions: (1) equatorial, tumor symmetry axis intersects the eye 
equator; (2) anterior, tumor symmetry axis is set 15° above the 
equator, which means 30° over the horizontal axis, and (3) poste-
rior, tumor symmetry axis is set 45° below the equator, that is, 60° 
below the horizontal axis. For all tumors, the apical height is con-
sidered from the tumor base. Equatorial tumors were modeled 
with the following apical heights: 3, 5, 6.5, 7, and 7.5 mm. Ante-
rior and posterior tumors were modeled with an apical height of 
3 mm. The distance from the posterior margin of the anterior and 
equatorial tumors to the papilla was 9.5 and 6.8 mm, respectively. 
The posterior margin of the posterior tumor overlapped by 2.8 
mm with the papilla.
For simulating the treatments of the considered tumor vol-
umes, the plaques were placed in different positions. For the 3-mm 
apical height anterior tumor, the homogeneous CCA plaque and 
the specific heterogeneous CCA1364 plaque were placed centri-
cally with respect to the tumor, that means, the symmetry axis of 
the plaque coincided with the symmetry axis of the tumor. The 
CCA1364 was also studied in an eccentric position, that is, the 
symmetry axis of the plaque did not coincide with the symmetry 
axis of the tumor. Instead, the edge of the plaque was made tangent 
to the basal edge of the tumor at a point. This placement disregards 
the commonly used safety margin of 2 mm between the plaque and 
the basal edge of the tumor. For the equatorial tumors, with apical 
heights ranging from 3 to 7.5 mm, the homogeneous CCA and 
CCB plaques, as well as the heterogeneous CCA1364 and CCB1256 
plaques, were all placed in a centric position. For the posterior tu-
mor of an apical height of 3 mm, the homogeneous CCA and the 
heterogeneous CCA1364 plaques were simulated in eccentric 
placement, that is, the edge of the plaques was made tangent to the 
basal edge of the tumor at a point. This placement is anatomically 
difficult to attain with this plaque model owing to the presence of 
the optic nerve. A second, more eccentric placement was simu-
lated for the heterogeneous CCA1364 plaque, which respected the 
anatomical position of the optic nerve. In this more eccentric 
placement, the plaque fell short of covering the whole basal surface 
of the tumor by a maximum distance of 0.3 mm. The heteroge-
neous CCB1256 was only placed equatorially, although it was also 
used for the eccentric treatment of the anterior and posterior tu-
mors. The equatorially placed CCB1256 plaque covered the whole 
anterior tumor and the edge of the plaque overlapped the basal 
edge of the tumor by at most 2.8 mm. Conversely, the equatorially 
placed CCB1256 plaque did not fully cover the whole posterior 
tumor, with its edge falling short of the basal edge of the tumor by 
at most 2.6 mm.
The orientation of the plaques, that is, rotations about their 
symmetry axes, was considered in order to study the influence of 
the heterogeneities of the emission map. The CCB1256 eye plaque 
has a well-defined hot spot [20]. Although the CCB1256 eye plaque 
was positioned only equatorially, it is necessary to determine the 
effect of the relative position of the hot spot with respect to the 
structures at risk on the dose distribution for the anterior and pos-
terior target volumes. In order to simulate the dose distribution in 
the anterior and posterior tumors, the CCB1256 plaque was ro-
tated to take advantage of the hot spot position, that means, the 
spot was oriented in each case towards the considered tumor. For 
the CCA1364 eye plaque, the distribution of the radioactive sub-
stance over the surface does not present a hot spot, but it is not 
symmetrically and homogeneously distributed [20]. In this case, 
and taking advantage of the deposition of the radioactive substance 
for the anterior and posterior placements, the CCA1364 eye plaque 
was placed eccentrically and rotated in the appropriate way to pro-
tect structures at risk, while maximizing the dose to the apex. Fig-
ures 1 and 2 show the eccentric placement of the CCA1364 eye 
plaque in an anterior and a posterior position, respectively, and 
tangent to the basal line of the tumor.
Dose Prescription
Delivery of the dose takes a certain period of time, which is re-
flected in the prescription method. Initially, the time required to 
reach 700 Gy at the sclera, determined at a point 2 mm away from 
the plaque along its symmetry axis, is computed using the data cor-
responding to the heterogeneous configuration of the plaques ob-
tained from a previous work [20]. For the computations presented 
herein, the aforementioned measured activities were used. These 
irradiation times are 132.8 h for treatments performed using the 
CCA1364 plaque and 93.8 h for treatments using the CCB1256 
plaque. If the computed irradiation time is long enough to deliver 
a dose greater than 100 Gy at the tumor apex, then the treatment 
is performed. If not, the time is extended until the dose delivered 
at the apex reaches 100 Gy. If the new time results in a dose to the 
sclera greater than 1,500 Gy, then a brachytherapy treatment with 
this plaque is not performed.
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For this study, an apical dose of 100 Gy was chosen to improve 
comprehensibility. This value is not a recommendation for clinical 
applications. In clinical reality at the Universitätsklinikum Essen, 
the dose prescribed to the tumor apex is 130 Gy. This value takes 
into consideration the uncertainties associated with the treatment 
and leads to a clinical target volume that includes the gross tumor 
volume safely.
Results and Discussion
For all simulations performed, the average standard 
statistical uncertainty of the dose is lower than 1%.
In Figure 3, dose-volume histograms (DVHs) are plot-
ted, obtained for the irradiations of an anterior 3-mm api-
cal height tumor. The plot shows DVHs for the tumor 
volume and for the eye lens. The considered irradiations 
in that figure are the simulations performed with the ge-
neric homogeneous CCA plaque, the specific heteroge-
neous CCA1364 plaque placed centrically with respect to 
the tumor as well as eccentrically with respect to it, and 
finally, the specific heterogeneous CCB1256 eye plaque 
placed eccentrically, too. It is observed that the CCA1364 
plaque placed centrically and the CCB1256 plaque placed 
eccentrically give similar coverage over the tumor vol-
ume. In terms of absolute dose, the maximum dose of 243 
Gy at the tumor apex corresponds to the CCA1364 eye 
plaque, while the dose delivered by the CCB1256 plaque 
is 1.5% lower. The CCA1364 plaque placed eccentrically 
delivers at the tumor apex a maximum dose 23% lower 
than the dose delivered at the apex by the CCA1364 
plaque placed centrically. With respect to the eye lens, the 
minimum dose of 91 Gy corresponds to the CCA1364 
plaque placed eccentrically. The dose absorbed by the eye 
lens is 221% higher when using the CCA1364 eye plaque 
placed centrically and 155% when using the CCB1256 eye 
plaque.
Figure 4 represents the DVHs obtained for the cornea 
and the eye lens during the irradiation of a 3-mm apical 
height tumor in anterior position. The heterogeneous 
CCA1364 eye plaque placed centrically with respect to the 
tumor delivers the maximum dose to the cornea, that is, 
44 Gy. This dose is 31% higher than the dose delivered by 
the heterogeneous CCB1256 and 49% higher than the 
dose delivered by the idealized homogeneous CCA eye 
plaque. The dose delivered to the cornea by the CCA1364 
plaque placed eccentrically is lower than 1 Gy.
It was found that the treatment with the CCA1364 eye 
plaque placed eccentrically with respect to the 3-mm an-
terior tumor, without respecting the 2-mm safety mar-
gin, was the most suitable treatment, among those con-
sidered, in terms of the of the obtained DVHs. This con-
figuration delivers the required dose at the tumor apex 
while minimizing the dose to the eye lens. It is also im-
portant to observe that the CCB1256 plaque placed ec-
centrically, on an equatorial position, delivers a smaller 
dose to the eye lens than the CCA1364 placed centri-
cally.
Figure 5 shows the DVHs obtained for the tumor vol-
ume and the optic disc during the simulated irradiation 
of a tumor of 3 mm of apical height located in a posterior 
position of the eye. In terms of absolute dose, the CCA1364 
eye plaque placed tangentially to the tumor delivers an 
apical dose of 158 Gy, which is the highest dose at the tu-
mor apex among the simulated scenarios. The CCA1364 
Fig. 1. Isodose lines corresponding to the 
CCA1364 eye plaque placed eccentrically 
in an anterior position with respect to an 
anterior tumor of an apical height of 3 mm 
without respecting the 2-mm safety margin 
at the base of the tumor. The tumor volume 
is shown with a blueish color wash. Num-
bers next to each isodose line indicate ab-
solute dose in Gy.
Fig. 2. Isodose lines corresponding to the 
CCA1364 eye plaque placed eccentrically 
in a posterior position with respect to a 
posterior tumor of an apical height of 3 mm 
without respecting the 2-mm safety margin 
at the base of the tumor. The tumor volume 
is shown with a reddish color wash. Num-
bers next to each isodose line indicate ab-
solute dose in Gy.
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plaque delivers a 1.5% smaller dose when its position does 
not fully cover the base of the tumor. The homogeneous 
CCA plaque in the tangent position delivers a dose being 
26% lower at the apex than the dose delivered by the 
CCA1364 in a tangent position. The CCB1256 plaque in 
the equatorial position delivers the lowest dose without 
reaching the reference dose of 100 Gy at the apex; this is 
49% lower than the dose delivered by the CCA1364 placed 
tangentially to the tumor. Regarding the optic disc, the 
CCA1364 plaque placed tangentially to the tumor deliv-
ers a maximum dose of 956 Gy in its volume. When using 
the CCA1364 eye plaque without covering the whole base 
of the tumor, the maximum dose received by the optic 
disc is 13% lower than the dose delivered when the 
CCA1364 eye plaque is placed tangentially to the tumor 
base. The lowest dose to the optic disc is delivered by the 
CCB1256 plaque; this is 66% lower than the dose deliv-
ered by the CCA1364 plaque placed tangentially to the 
tumor.
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Fig. 3. Dose-volume histograms obtained for the eye lens and the 
anterior tumor volume of an apical height equal to 3 mm. The la-
bels correspond to the following irradiations: “CCA” is a homoge-
neously distributed plaque placed centrically with respect to the 
tumor, “CCA1364” is the heterogeneously distributed plaque 
placed centrically, “CCA1364 eccentric” is the heterogeneous 
plaque placed eccentrically with the edge of the plaque made tan-
gent to the basal edge of the tumor at a point, “CCB1256” is the 
heterogeneous plaque placed equatorially, that is eccentrically, and 
it covered the whole anterior tumor while the edge of the plaque 
overlapped the basal edge of the tumor by at most 2.8 mm. In all 
cases where heterogeneous plaques were used, they were oriented 
taking advantage of their heterogeneity to maximize the dose at the 
tumor volume and to minimize the dose at the structures at risk.
Fig. 4. Dose-volume histograms obtained for the cornea and the 
eye lens during the irradiation of a 3-mm apical height tumor in 
anterior position. The positions and orientations of the plaques 
indicated in the plots follow the same description given in the cap-
tion of Figure 3.
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Fig. 5. Dose-volume histograms obtained for the tumor volume 
and the optic disc during the irradiation of a tumor of 3 mm of 
apical height located in a posterior position. The labels “CCA fea-
sible” and “CCA1364 feasible” indicate an eccentric placement of 
the homogeneous and heterogeneous plaques, respectively, in 
which the whole base of the tumor is not covered owing to the pres-
ence of the optic nerve. In this placement, the plaque falls short by 
at most 0.3 mm to cover the base of the tumor. The label “CCA1364 
eccentric” indicates an eccentric placement of the plaque in which 
the basal edge of the tumor is tangent to the edge of the plaque, a 
treatment which is not feasible due to the presence of the optic 
nerve. The label “CCB1256” indicates an equatorially located 
plaque that eccentrically treats the tumor. Its edge falls short by, at 
most, 2.6 mm to cover the base of the tumor.
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For tumors of 3 mm of apical height in a posterior po-
sition, it was found that the CCA1364 eye plaque placed 
eccentrically and not fully covering the base of the tumor 
by at most 0.3 mm delivers the most suitable treatment, 
among those considered, in terms of the studied DVHs. 
For this tumor height and location, the most conservative 
treatment with respect to the optic disc is given by the 
CCB1256 plaque in an equatorial placement although the 
criterion of 100 Gy at the apex is not achieved.
In Figure 6, the DVHs corresponding to the treatment 
of equatorial tumors of 3 and 5 mm of apical height are 
plotted, using for the simulation the dose criterion of 700 
Gy at the sclera. For tumors of 3 mm of apical height, the 
maximum apical dose is 237 Gy, delivered by the CCB1256 
plaque. The CCA1364 delivers a 7% smaller dose and the 
homogeneous CCA and CCB plaques deliver a 34 and 
54% lower dose than the CCB1256 plaque, respectively. 
With respect to the tumor of 5 mm of apical height, the 
best coverage and maximum dose of 107 Gy at the apex 
is given by the CCB1256 plaque. The CCA1364 delivers 
an 18% smaller dose than the CCB1256 plaque, therefore 
not reaching the required dose of 100 Gy at the tumor 
apex. For this tumor size, the homogeneous CCA and 
CCB plaques do not accomplish the treatment criterion 
of 100 Gy at the tumor apex, while delivering 700 Gy to 
the sclera.
For tumors with an apical height of less than 5 mm in 
equatorial position and taking into consideration the cri-
terion of 700 Gy at the sclera, the CCB1256 eye plaque 
succeeds with a good coverage of the tumor volume. The 
CCA1364 eye plaque does not succeed for a tumor of 
5 mm of apical height since the dose delivered at the apex 
is 88 Gy.
For tumors of a height larger than 5 mm, the criterion 
to extend the irradiation time until the dose at the tumor 
apex reaches 100 Gy must be used. DVHs of the tumor 
volume, the optic disc, and the eye lens are plotted in Fig-
ure 7 for the irradiations considering equatorial tumors 
of apical heights of 6.5, 7, and 7.5 mm. For tumors of 6.5 
mm of apical height, the CCA1364 and the CCB1256 
plaques do not exceed the dose of 1,500 Gy at the sclera 
in order to reach 100 Gy at the apex. The CCB1256 plaque 
is the most conservative one delivering 1,182 Gy; the 
CCA1364 delivers a 25% higher dose than the CCB1256 
at the sclera. According to the dose prescription present-
ed at the end of section 2, tumors of 7 and 7.5 mm cannot 
be treated because the maximum dose of 1,500 Gy al-
lowed at the sclera cannot be respected.
Tumors of 6.5 mm of apical height can be treated with 
the CCA1364 and CCB1256 eye plaques. Both plaques 
succeed without delivering more than 1,500 Gy at the 
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Fig. 6. Dose-volume histograms calculated for the tumor volume 
on tumors of 3 and 5 mm of apical height placed in an equatorial 
position. All plaques are centrically placed.
Fig. 7. Dose-volume histograms (DVHs) calculated for the tumor 
volume, the optic disc and the eye lens when treating tumors of 6.5, 
7, and 7.5 mm of apical height placed in an equatorial position. All 
plaques are centrically placed. According to our criteria, the treat-
ment of tumors with apical height of 7 and 7.5 mm should not be 
considered since the required dose at the sclera in order to reach 
100 Gy at the apex is 1,673 and 1,920 Gy, respectively. Neverthe-
less, the DVHs of the tumor volume for these large tumors are 
plotted.
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sclera. The most conservative treatment with respect to 
the eye lens and the optic disc is given by the CCA1364 
eye plaque. For tumors of an apical height larger than 
7 mm all plaques deliver doses at the sclera that exceed 
the limit considered previously.
Conclusions
The heterogeneous distribution of the activity at the 
active layer of the applicator has an important contribu-
tion to the dose distribution in the irradiated volume and 
might be used to the benefit of the patient. By taking ad-
vantage of the heterogeneous distribution of the emitter 
map, it is possible to reduce the dose to structures at risk 
and to increase the applied dose to the tumor volume. In 
general, the emitter map of every single plaque is not 
known, hence it must be measured with specific experi-
mental setups that are not part of the routine clinical 
practice. Currently there is no such system that allows 
routine measurements of the emitter map and its usage in 
the subsequent Monte Carlo simulation. Therefore, the 
heterogeneous activity distribution of the plaque has to 
be considered as another uncertainty which might be-
come relevant when treating tumors with an apical height 
larger than 3 mm.
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